Glaxosmithkline Share News (GSK)

LONDON MARKET MIDDAY: Stocks down over US rate hike worries

(Alliance News) - Stock prices in Europe were lower at midday on Thursday, after the US Federal Reserve warned that a further interest rate hike may be on the cards.

LONDON MARKET OPEN: Stocks fall further after hawkish US Fed minutes

(Alliance News) - Stock prices in London opened in the red on Thursday, amid renewed concerns about further US interest rate increases.

Sunday newspaper round-up: White Hydrogen, Bank of England, AI

(Sharecast News) - America's Geological survey estimates that if even a small fraction of naturally occurring - and clean or so-called 'white' - hydrogen beneath the earth's surface were recovered, that would last for hundreds of years. Among the backers of the hydrogen industry is Bill Gates, who ploughed $90m into Koloma, a company hunting for natural hydrogen along the US's Midcontinental Rift System. White hydrogen has also been discovered in Europe, in France's Lorraine region. Nonetheless, the true potential of the stuff will hinge on the findings from those early projects, says Philip Ball, research fellow at Keele University. - Guardian

UK dividends calendar - next 7 days

PRESS: Inflexion among firms looking to buy Haleon's nicotine business

(Alliance News) - Sky News reported on Sunday that Inflexion Private Equity Partners is among suitors for Haleon PLC's Nicotinell anti-smoking aid.

GSK Nigeria calls an end to its business, to return cash

ABUJA, Aug 3 (Reuters) - GlaxoSmithKline (GSK) Nigeria said on Thursday it plans to stop doing business after evaluating the options for moving to a third-party distribution model for its drugs and consumer healthcare goods.

TOP NEWS: GSK sues Pfizer over patent infingements for RSV vaccine

(Alliance News) - GSK PLC on Wednesday sued Pfizer Inc over patent infringement, alleging Pfizer's respiratory syncytial virus vaccine steals key elements of GSK's version.

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in a U.S. court on Wednesday, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's patent rights in its rival RSV shot Arexvy.

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK's patent rights in its rival RSV shot Arexvy.

Sensodyne maker Haleon's shiny forecast signals price hikes unlikely to dent demand

Shares down 1% on slight decline in H1 adj operating margin

*

TOP NEWS: Haleon boosts annual guidance after solid first half

(Alliance News) - Haleon PLC on Wednesday upped its annual organic revenue growth guidance following a solid revenue performance in the first half of 2023.

IN BRIEF: GSK hails US FDA approval for cancer treatment, Jemperli

GSK PLC - London-based pharmaceutical company - Jemperli plus chemotherapy approved in the US by the Food & Drug Administration as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer. Notes Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy. Hesham Abdullah, senior vice president and global head of oncology development at GSK, says: "Today's approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy."

DIRECTOR DEALINGS: Qinetiq, Tesco and GSK executives sell shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced late last week and not separately reported by Alliance News:

LONDON BROKER RATINGS: Oddo BHF raises IAG to 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

GSK raises 2023 outlook boosted by vaccine, HIV drug sales

Q2 sales and earnings beat estimates

*